Janssen and MeiraGTx team up to fight inherited retinal diseases
MeiraGTx has announced a strategic collaboration with Johnson & Johnson’s Janssen to develop and commercialise gene therapy treatments for inherited retinal diseases (IRDs).
Read More
Tag: IRD
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
